Biogen, Dravet and Stoke Therapeutics

Biogen and Stoke Strike Dravet Syndrome Co-Development Deal
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential payments due to Stoke.
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet syndrome is a genetic developmental and epileptic encephalopathy characterised by cognitive and behavioural impairments and recurrent seizures.
Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally
Biogen (NASDAQ:BIIB) and Stoke Therapeutics (NASDAQ:STOK) said on Tuesday they are collaborating to develop and commercialize zorevunersen, an investigational treatment for Dravet syndrome, in territories outside the United States,
Biogen, Stoke Partner on Zorevunersen in Dravet Syndrome
Biogen receives exclusive rights to commercialize zorevunersen outside U.S., Europe, and Japan.
Biogen Inks Deal to Commercialize Stoke Therapeutics' Dravet Syndrome ASO; Stoke Retains US Rights
Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.
Biogen, Stoke Therapeutics Set Dravet Syndrome Collaboration
Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions of dollars to Stoke.
Biogen partners with Stoke Therapeutics on drug for severe epilepsy
Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, outside the U.S.
News Medical on MSN2d
Gene therapy breakthrough offers hope for severe Dravet syndrome cases
AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
FierceBiotech2d
Biogen pays Stoke $165M, bagging Dravet prospect to fire up late-phase pipeline
The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...